Results 301 to 310 of about 6,020,192 (375)

Antifibrotic effects of specific targeting of the 5‐hydroxytryptamine 2B receptor (5‐HT2BR) in murine models and ex vivo models of scleroderma skin

Arthritis &Rheumatology, EarlyView.
Objective Systemic sclerosis (SSc) is a connective tissue disease with fibrotic remodeling of the skin and various internal organs. SSc is associated with the highest case‐specific mortality of all rheumatic autoimmune diseases with limited antifibrotic treatment options.
Thuong Trinh‐Minh, Cuong Tran‐Manh, Andrea‐Hermina Györfi, Nicholas Dickel, Christoph Liebel, Xiang Zhou, Jiucun Wang, Meik Kunz, Helena Arozenius, Lars Pettersson, Sam Lindgren, Christina Wenglén, Jörg H. W. Distler   +12 more
wiley   +1 more source

Digital remote monitoring of people with multiple sclerosis. [PDF]

Front Immunol
Dini M, Comi G, Leocani L.
europepmc   +1 more source

Clinical factors associated with pneumocystis pneumonia despite its primary prophylaxis: When to stop prophylaxis?

Arthritis &Rheumatology, Accepted Article.
Objective Although previous studies show that primary prophylaxis against Pneumocystis jirovecii pneumonia (PJP) is effective in patients with rheumatic diseases receiving immunosuppressive treatment, there is limited evidence regarding the optimal timing for prophylaxis withdrawal.
Ju Yeon Kim, Se Rim Choi, Jin Kyun Park, Eun Young Lee, Eun Bong Lee, Jun Won Park   +5 more
wiley   +1 more source

The role of NLRP3 inflammasome in multiple sclerosis: pathogenesis and pharmacological application. [PDF]

Front Immunol
Zhang WG, Zheng XR, Yao Y, Sun WJ, Shao BZ.   +4 more
europepmc   +1 more source

CHI3L1 in Multiple Sclerosis-From Bench to Clinic. [PDF]

Cells
Jatczak-Pawlik I, Jurewicz A, Domowicz M, Ewiak-Paszyńska A, Stasiołek M.   +4 more
europepmc   +1 more source

Pathogenetic Involvement of Autophagy and Mitophagy in Primary Progressive Multiple Sclerosis. [PDF]

J Cell Mol Med
Patergnani S, Laudisi M, Bonora M, Righes G, Straudi S, Wieckowski MR, Casetta I, Semenzato L, Koutsikos K, Zanato V, Giorgi C, Pinton P.   +11 more
europepmc   +1 more source

Myelopoiesis is temporally dynamic and is regulated by lifestyle to modify multiple sclerosis. [PDF]

Nat Commun
Yates AG, Khamhoung A, Gaebel L, Jacob W, Radford-Smith DE, Kiss MG, Huynh P, Gerhardt T, Heiser M, Cohen O, Swirski FK, Anthony DC, Sumowski J, Katz Sand I, McAlpine CS.   +14 more
europepmc   +1 more source

Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim TAS5315 is a Bruton tyrosine kinase (Btk) inhibitor in development for autoimmune and allergic diseases, including rheumatoid arthritis (RA) and chronic spontaneous urticaria (CSU). Two clinical studies evaluated the pharmacology and safety of single and multiple oral doses of TAS5315.
Yuji Kumagai, Tomoe Fujita, Mika Maeda, Akiko Yamamoto, Hideki Amano   +4 more
wiley   +1 more source

Uncinate Fasciculus Lesion Burden and Anxiety in Multiple Sclerosis.

JAMA Netw Open
Baller EB, Luo AC, Schindler MK, Cooper EC, Pecsok MK, Cieslak MC, Martin ML, Bar-Or A, Elahi A, Perrone CM, Spangler BC, Satterthwaite TD, Shinohara RT.   +12 more
europepmc   +1 more source

Linking Pathogenesis to Fall Risk in Multiple Sclerosis. [PDF]

Arch Intern Med Res
Patel J, Fraix MP, Agrawal DK.
europepmc   +1 more source